Email
RSS26/11/08 - 09:05 ... source : World Health Organization
... further research Related links WHO and HIV/AIDS 26 November 2008 | GENEVA -- Universal and annual voluntary testing followed by immediate antiretroviral therapy treatment ((irrespective of clinical stage or CD4 count) can reduce new HIV ...
25/11/08 - 18:04 ... source : Memorial Hermann
... the first hospital in South Texas and only one of five facilities in the nation to be home to the Trilogy System for treating brain, spinal cord cancer and other central nervous system disorders with ...
25/11/08 - 15:52 ... source : Government Of Nova Scotia
... the best electronic medical record programs in the country is being used to improve health care in Nova Scotia by enhancing the way patient medical information is transferred and managed. The electronic medical record program, ...
25/11/08 - 08:15 ... source : American Society for Therapeutic Radiology and Oncology - ASTRO
24/11/08 - 22:21 ... source : Concert Pharmaceuticals
... announced today that it will be presenting at the 20th Annual Piper Jaffray Health Care Conference, being held at The New York Palace in New York City. Roger Tung, Ph.D., President and Chief Executive Officer ...
24/11/08 - 17:32 ... source : Johnson & Johnson
24/11/08 - 11:23 ... source : Genentech
... PFS Benefit With Capecitabine, As Well As With Anthracycline-Based Chemotherapies -- South San Francisco, Calif. -- November 23, 2008 -- Genentech, Inc. (NYSE:DNA) today announced that a Phase III study (RIBBON 1) of Avastin® (bevacizumab), ...
22/11/08 - 06:39 ... source : NPS Pharmaceuticals
... Inc. (Nasdaq: NPSP) announced today that Francois Nader, M.D., president and chief executive officer, is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference in New York on Wednesday, December 3, 2008 ...
22/11/08 - 05:28 ... source : Amgen
... and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin ...
